News

CEO, Anders Hultman, Commenting on FDA delay due to Covid-19

Jan 20, 2021

This weekend the US Food and Drug Administration (FDA) has informed that the impact of the COVID-19 pandemic and the reallocation of staff is leading to an even greater prolonged timeline for reviews of submissions. Anders Hultman, CEO of AroCell, commenting the FDA delay in an interview with Redeye.

Gustav Sten appointed CEO of IDL Diagnostics

May 19, 2026 |

IDL Diagnostics today announces that the Board of Directors has appointed Gustav Sten as the new Chief Executive Officer (CEO). Gustav Sten will assume the position on May 28, immediately following the Annual General Meeting, succeeding Anders Hultman.  Gustav Sten...

read more

Healthcare day 2026

Apr 16, 2026 | ,

On April 14, IDL participated at Redeye Healthcare Day. CEO Anders Hultman presented the company and shared more about its strategy, current and future markets, and our joint venture with concile. Watch the presentation here

read more